Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 12:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 2,208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)

NCT00862745
View directory record Official record
Conditions
Urge Urinary Incontinence, Overactive Bladder
Interventions
Fesoterodine, Matching Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
645 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

NCT00021541
View directory record Official record
Conditions
Neurofibroma, Plexiform, Neurofibromatosis Type I
Interventions
tipifarnib, placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 25 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults

NCT00557583
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
VBY 376
Drug
Lead sponsor
Virobay Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers

NCT01931059
View directory record Official record
Conditions
Imaging of the Brain and Antipsychotics, Neuronal Network Changes
Interventions
Risperidone, Placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02107196
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
65
States / cities
Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough EKG Safety Study of TA-1790 (Avanafil)

NCT00769041
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
moxifloxacin, avanafil, sugar pill
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 7, 2011 · Synced Oct 16, 2026, 12:59 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

NCT06630286
View directory record Official record
Conditions
HIV-1-infection
Interventions
ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars

NCT00754247
View directory record Official record
Conditions
Keloid, Hypertrophic Scar, Cicatrix, Hypertrophic
Interventions
0.5% hydrocortisone, silicone, vitamin E lotion, Onion extract gel, Cetearyl alcohol lotion
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Unacylated Ghrelin to Improve Functioning in PAD

NCT04377126
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Ghrelin, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
55 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant

NCT01305200
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Mucositis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
supersaturated calcium phosphate rinse, placebo, questionnaire administration, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 21 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
31
States / cities
Arcadia, California • Duarte, California • Oakland, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Phase 1Phase 2 Interventional

A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1

NCT02312011
View directory record Official record
Conditions
Myotonic Dystrophy Type 1
Interventions
IONIS-DMPKRx, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Stanford, California • Gainesville, Florida • Kansas City, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Phase 4 Interventional

Premedication for Less Invasive Surfactant Administration Study (PRELISA)

NCT05065424
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Hours to 72 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 16, 2026, 12:59 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

NCT06436742
View directory record Official record
Conditions
Congenital Myasthenic Syndrome, CMS
Interventions
ARGX-119, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Sacramento, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

NCT04539041
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
antisense oligonucleotide, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
La Jolla, California • Rochester, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 16, 2026, 12:59 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

NCT04484818
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Darolutamide, Goserelin Acetate, Leuprolide Acetate, Placebo Administration, Quality-of-Life Assessment, Triptorelin
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
115
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 88 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer

NCT01619423
View directory record Official record
Conditions
Advanced Metastatic (Stage IV) Colorectal Cancer
Interventions
PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg), Placebo (0,9% NaCl)
Drug
Lead sponsor
Egetis Therapeutics AB (publ)
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
La Jolla, California • Bethesda, Maryland • Chattanooga, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Early Phase 1 Interventional Results available

Neurophysiological and Acute Pharmacological Studies in FXS Patients

NCT02998151
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Acamprosate, Lovastatin, Minocycline, Placebo, Baclofen
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
15 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

NCT03293498
View directory record Official record
Conditions
Influenza
Interventions
NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21, Saline - Day 21
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Raleigh, North Carolina • Rocky Mount, North Carolina • Statesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 16, 2026, 12:59 AM EDT
Recruiting Phase 3 Interventional

Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy

NCT06969326
View directory record Official record
Conditions
Postoperative Bleeding, Gender Dysphoria, Hysterectomy
Interventions
Use of topical estradiol, No intervention
Drug · Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Phase 4 Interventional Results available

A Comparison of Intra-op Ketamine vs Placebo in Patients Having Spinal Fusion

NCT02424591
View directory record Official record
Conditions
Postoperative Pain
Interventions
Ketamine, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 16, 2026, 12:59 AM EDT
Terminated Phase 2 Interventional Results available

Zinc and Green Tea Extract for Community Respiratory Viral Infections

NCT04898023
View directory record Official record
Conditions
Respiratory Viral Infection
Interventions
zinc-green tea extract-ascorbic acid, Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

NCT03739866
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Lenacapavir, Placebo, B/F/TAF, TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Sacramento, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 16, 2026, 12:59 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat

NCT07140939
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9% Sodium Chloride
Drug · Other
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
11
States / cities
Encinitas, California • West Palm Beach, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 16, 2026, 12:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

NCT06422767
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 16, 2026, 12:59 AM EDT